Shimada Lab

Dr. Yuichi Shimada, MD, MPH, is Research Director of the Hypertrophic Cardiomyopathy Center and Associate Professor of Medicine at Columbia University Irving Medical Center. He is also a Faculty of the Frontiers in Cardiovascular Discovery Workshop as a part of the Body in Health and Disease Course at Columbia University Vagelos College of Physicians and Surgeons.

Dr. Shimada received MD degree from The University of Tokyo in 2007. He was selected as one of the 2 exchange medical students who were allowed to experience a three-month sub-internship at Johns Hopkins Hospital, where he decided to pursue his career as a physician-scientist in the United States. After graduation, he served as a house staff at the University of Tokyo Hospital (2007-2008).

Dr. Shimada completed Internal Medicine residency at Beth Israel Medical Center (2008-2011) and was selected as Chief Medical Resident (2011-2012). He moved on to cardiology fellowship at Brigham & Women’s Hospital, Harvard Medical School (2012-2015). He also honed his clinical research skills at TIMI Study Group and Harvard Clinical Research Institute during the fellowship. He spent the last year of his cardiology fellowship as the first “hypertrophic cardiomyopathy fellow” at Massachusetts General Hospital, Harvard Medical School (2014-2015). Concurrently with his residency and fellowship, he enrolled in the Master of Public Health Program at Johns Hopkins (2011-2014) and was inducted into the Delta Omega Alpha Public Health Honor Society at Hopkins.

After graduating from his fellowship in 2015, Dr. Shimada served as an attending cardiologist of the Hypertrophic Cardiomyopathy Program at Massachusetts General Hospital (2015-2017). He joined the faculty of the Division of Cardiology at Columbia University Irving Medical Center in 2017.

Dr. Shimada has served as an ad-hoc reviewer/judge for research grant funding systems of American Heart Association (5 times), University of Muenster (Germany), and Swiss National Science Foundation (twice). He is an editorial board member of 3 peer-reviewed scientific journals. He has performed peer-review as an ad-hoc reviewer for >40 scientific journals, and the list includes top journals such as Circulation, European Heart Journal, Journal of the American College of Cardiology, JAMA Cardiology, and Annals of Internal Medicine. He has also received multiple awards and prizes for his research and gave >100 invited lectures nationally and internationally (e.g., Portugal, Korea, and Japan). Dr. Shimada has been a site investigator and site principal investigator of several multi-center, international, randomized controlled trials on hypertrophic cardiomyopathy and heart failure. Additionally, Dr. Shimada serves as a Board Member and Chair of Scholarship Committee at Japanese Medical Society of America.

• Liang LW, Hasegawa K, Maurer MS, Fifer MA, Reilly MP, Shimada YJ. Comprehensive Transcriptomics Profiling of microRNA Reveals Plasma Circulating Biomarkers of Hypertrophic Cardiomyopathy and Dysregulated Signaling Pathways. Circulation: Heart Failure. In press.
• Miyashita S, Akita K, Zhao Y, Hasegawa K, Maurer MS, Weiner SD, Reilly MP, Takayama H, Shimada YJ. Bariatric surgery is associated with lower risk of acute cardiovascular event in patients with obesity and hypertrophic cardiomyopathy. ESC Heart Failure. In press.
• Lander BS, Zhao Y, Hasegawa K, Maurer MS, Tower-Rader A, Fifer MA, Reilly MP, Shimada YJ. Comprehensive proteomics profiling identifies patients with late gadolinium enhancement on cardiac magnetic resonance imaging in the hypertrophic cardiomyopathy population. Front Cardiovasc Med. 2022;9:839409. PMID: 35783832.
• Liang LW, Raita Y, Hasegawa K, Fifer MA, Maurer MS, Reilly MP, Shimada YJ. Proteomics profiling reveals a distinct high-risk molecular subtype of hypertrophic cardiomyopathy. Heart. 2022:heartjnl-2021-320729. PMID: 35351822.
• Liang LW, Kalia I, Latif F, Waase MP, Shimada YJ, Sayer G, Reilly MP, Uriel N. The use of telemedicine in cardiogenetics clinical practice during the COVID-19 pandemic. Mol Genet Genomic Med. 2022;10(6):e1946. PMID: 35388985.
• Morita SX, Hasegawa K, Raita Y, Reilly MP, Fifer MA, Maurer MS, Shimada YJ. Effects of septal reduction therapy on acute cardiovascular events and all-cause mortality in patients with obstructive hypertrophic cardiomyopathy: propensity score-matched study. Int Heart J. 2021;62(5):1035-1041. PMID: 34544977.
• Shimada YJ, Raita Y, Maurer MS, Hasegawa K, Fifer MA, Reilly MP. Prediction of major adverse cardiovascular events in patients with hypertrophic cardiomyopathy using proteomics profiling. Circulation: Genomics and Precision Medicine. 2022:e003546. PMID: 36252118. Press release from NewYork-Presbyterian/ Columbia University Irving Medical Center (https://www.nyp.org/advances-cadiology/hypertrophic-cardiomyopathy-addre...)
• Shimada YJ, Raita Y, Liang LW, Maurer MS, Hasegawa K, Fifer MA, Reilly MP. Comprehensive proteomics profiling reveals circulating biomarkers of hypertrophic cardiomyopathy. Circulation: Heart Failure. 2021;14(7):e007849. PMID: 34192899.
• Liang LW, Fifer MA, Hasegawa K, Maurer MS, Reilly MP, Shimada YJ. Prediction of genotype positivity in patients with hypertrophic cardiomyopathy using machine learning. Circulation: Genomics and Precision Medicine 2021;14(3):e003259. PMID: 33890823.
• Morita SX, Kusunose K, Haga A, Sata M, Hasegawa K, Raita Y, Reilly MP, Fifer MA, Maurer MS, Shimada YJ. Deep learning analysis of echocardiographic images to predict positive genotype in patients with hypertrophic cardiomyopathy. Front Cardiovasc Med. 2021;8:669860. PMID: 34513940.
• Kochav SM, Raita Y, Fifer MA, Takayama H, Ginns J, Maurer MS, Reilly MP, Hasegawa K, Shimada YJ. Machine learning-based prediction of cardiovascular death in patients with hypertrophic cardiomyopathy. Int J Cardiol. 2020:S0167-5273(20)34077-8. PMID: 33181159.
• Shimada YJ, Batra J, Kochav SM, Patel P, Jung J, Maurer MS, Hasegawa K, Reilly MP, Fifer MA. Difference in metabolomic response to exercise between patients with and without hypertrophic cardiomyopathy. J Cardiovasc Transl Res. 2021;14(2):246-255. PMID: 32594362.
• Kuno T, Takagi H, Ando T, Sugiyama T, Miyashita S, Valentin N, Shimada YJ, Kodaira M, Numasawa Y, Briasoulis A, Burger A, Bangalore S. Oral anticoagulation for patients with atrial fibrillation on long-term hemodialysis. J Am Coll Cardiol. 2020;75(3):273-285. PMID: 31976865.
• Shimada YJ, Goto T, Takayama H, Brown DFM, Homma S, Maurer MS, Reilly MP, Hasegawa K. Comparison of effectiveness of alcohol septal ablation versus ventricular septal myectomy on acute care use for cardiovascular disease in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2019;124(8):1272-1278. PMID: 31447010.
• Shimada YJ, Hasegawa K, Kochav SM, Mohajer P, Jung J, Maurer MS, Reilly MP, Fifer MA. Application of proteomics profiling for biomarker discovery in hypertrophic cardiomyopathy. J Cardiovasc Transl Res. 2019;12(6):569-579. PMID: 31278493.
• Shimada YJ, Hoeger CW, Latif F, Takayama H, Ginns J, Maurer MS. Myocardial contraction fraction predicts cardiovascular events in patients with hypertrophic cardiomyopathy and normal ejection fraction. Journal of Cardiac Failure. 2019;25(6):450-456. PMID: 30928539.
• Shimada YJ, Goto T, Tsugawa Y, Yu EW, Yoshida K, Homma S, Brown DFM, Hasegawa K. Comparative effectiveness of gastric bypass versus gastric banding on acute care use for cardiovascular disease in obese adults. Nutrition, Metabolism, and Cardiovascular Diseases. 2019;29(5):518-526. PMID: 30935764.
• Shimada YJ, Hasegawa K, et al. Bariatric surgery is associated with lower risk of acute care use for cardiovascular disease in obese adults. Cardiovascular Research. 2019;115(4):800-806. PMID: 30357327.
• McCullough SA, Fifer MA, Mohajer P, Lowry PA, Reen CO, Baggish AL, Vlahakes GJ, Shimada YJ. Clinical correlates and prognostic impact of elevated right atrial pressure in patients with hypertrophic cardiomyopathy. Circulation Journal. 2018;82(5):1405-1411. PMID: 29526913.
• Shimada YJ, Tsugawa Y, Iso H, Brown DFM, Hasegawa K. Association of bariatric surgery with risk of acute care use for hypertension-related disease in obese adults: population-based self-controlled case series study. BMC Med. 2017;15(1):161. PMID: 28830535.
• Shimada YJ, Tsugawa Y, Camargo CA, Brown DFM, Hasegawa K. Effect of bariatric surgery on emergency department visits and hospitalizations for atrial fibrillation. Am J Cardiol. 2017;120(6):947-952. PMID: 28734462.
• Shimada YJ, Tsugawa Y, Iso H, Brown DFM, Hasegawa K. Association between bariatric surgery and risk of hospitalizations for stable angina pectoris in obese adults. Heart. 2017;103(13):1009-1014. PMID: 28209590.
• Shimada YJ, Bansilal S, Wiviott SD, Becker RC, Harrington RA, Himmelmann A, Neely B, Husted S, James SK, Katus HA, Lopes RD, Steg PG, Storey RF, Wallentin L, Cannon CP; PLATO Investigators. Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared to clopidogrel in patients with acute coronary syndromes - analysis from the PLATO (Platelet Inhibition and Patient Outcomes) trial. American Heart Journal. 2016;177:1-8. PMID: 27297843.
• Shimada YJ, Cannon CP, Liu Y, Wilson C, Kupfer S, Menon V, Cushman WC, Mehta CR, Bakris GL, Zannad F, White WB. Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the EXAMINE trial. American Heart Journal. 2016;175:18-27. PMID: 27179720.
• Shimada YJ, Tsugawa Y, Brown DFM, Hasegawa K. Association between bariatric surgery and rate of emergency department visits and hospitalizations for heart failure exacerbation among obese patients with heart failure. J Am Coll Cardiol. 2016;67(8):895-903. PMID: 26916477. Press release from Massachusetts General Hospital.
• Shimada YJ, Yamashita T, Koretsune Y, Kimura T, Abe K, Sasaki S, Mercuri M, Ruff CT, Giugliano RP. Effects of regional differences in Asia on efficacy and safety of edoxaban compared to warfarin: insights from the ENGAGE AF-TIMI 48 trial. Circulation Journal. 2015;79(12):2560-2567. PMID: 26460886.
• Shimada YJ, Passeri JJ, Baggish AL, O'Callaghan C, Lowry PA, Yannekis G, Abbara S, Ghoshhajra BB, Rothman RD, Ho CY, Januzzi JL, Seidman CE, Fifer MA. Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy. JACC: Heart Failure. 2013;1(6):480-487. PMID: 24621999.
• Funakoshi T, Shimada YJ. Risk of hypothyroidism in patients with cancer treated with sunitinib: a systematic review and meta-analysis. Acta Oncol. 2013;52(4):691-702. PMID: 23282114.
• Shimada YJ, Po JR, Kanei Y, Schweitzer P. Prognostic impact of terminal T wave inversions on presentation in patients with ST-elevation myocardial infarction undergoing urgent percutaneous coronary intervention. J Electrocardiol. 2013;46(1):2-7. PMID: 23312357.
• Shimada YJ, Shiota T. Underestimation of left atrial volume by 3-dimensional echocardiography validated by magnetic resonance imaging: a meta-analysis and investigation of the source of bias. Echocardiography. 2012;29(4):385-390. PMID: 22150607.
• Shimada YJ, Nakra NC, Fox JT, Kanei Y. Meta-analysis of prospective randomized controlled trials comparing intracoronary versus intravenous abciximab in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol. 2012;109(5):624-628. PMID: 22152971.
• Kato S, Shimada YJ (first co-author), Friedmann P, Kashan G, Husk G, Bergmann SR. Identification of residual risk factors for the development of venous thromboembolism in medical inpatients receiving subcutaneous heparin therapy for prophylaxis. Coron Artery Dis. 2012;23(4):294-297. PMID: 22421548.
• Shimada YJ, Shiota T. Meta-analysis of accuracy of left ventricular mass measurement by three-dimensional echocardiography. Am J Cardiol. 2012;110(3):445-452. PMID: 22541420.
• Shimada YJ, Ishikawa K, Kawase Y, Ladage D, Tilemann L, Shiota T, Hajjar RJ. Comparison of left ventricular stroke volume assessment by two- and three-dimensional echocardiography in a swine model of acute myocardial infarction validated by thermodilution method. Echocardiography. 2012;29(9):1091-1095. PMID: 22672366.
• Shimada YJ, Shiota T. A meta-analysis and investigation for the source of bias of left ventricular volumes and function by three-dimensional echocardiography in comparison with magnetic resonance imaging. Am J Cardiol. 2011;107(1):126-138. PMID: 21146700.
• Shimada YJ, Nakra NC, Fox TJ, Kanei Y. Relation of race to activated clotting time after weight adjusted bolus of heparin during percutaneous coronary intervention. Am J Cardiol. 2010;105(5):629-632. PMID: 20185008.
• Shimada YJ, Shiota M, Siegel RJ, Shiota T. Accuracy of right ventricular volumes and function determined by three-dimensional echocardiography in comparison with magnetic resonance imaging: a meta-analysis study. J Am Soc Echocardiogr. 2010;23(9):943-953. PMID: 20797527.

• Sewanan LR, Shimada YJ. Prospects for remodeling the hypertrophic heart with myosin modulators. Front Cardiovasc Med. 2022;9:1051564. PMID: 36330009.
• Liang LW, Shimada YJ. Response by Liang and Shimada to Letter Regarding Article "Comprehensive Proteomics Profiling Reveals Circulating Biomarkers of Hypertrophic Cardiomyopathy". Circ Heart Fail. 2022;15(6):e009568. PMID: 35727883.
• Love N, Shimada YJ. Japanese Medical Mnemonics-Language, Reflection, and Art. JAMA. 2021;326(13):1238-1240. PMID: 34609474.
• Nguyen SN, Blitzer D, Haythe J, Shimada YJ, Weiner SD, Takayama H. Commentary: What's a girl like you doing with a heart like this? J Thorac Cardiovasc Surg. 2021 Dec 9:S0022-5223(21)01736-0. PMID: 34998596.
• Liang LW, Shimada YJ [last author]. Endotyping in Heart Failure: Identifying mechanistically meaningful subtypes of disease[review]. Circ J. In press. PMID: 34108305.
• Nguyen SN, Shimada YJ, Weiner SD, and Takayama H. Atrial Fibrillation, Statin, and Septal Myectomy. [commentary]. Semin Thorac Cardiovasc Surg. 2021:S1043-0679(21)00031-9. PMID: 33600974.
• Nguyen SN, Weiner SD, Shimada YJ, and Takayama H. Latent Gradient, latent messages in Hypertrophic Cardiomyopathy[commentary]. The Journal of Thoracic and Cardiovascular Surgery. 2021;S0022-5223(21)00136-7. PMID: 33581905.
• Nguyen SN, Shimada YJ, Weiner SD, and Takayama H. Just Do It?[commentary]. The Journal of Thoracic and Cardiovascular Surgery. 2020;S0022-5223(20)32908-1. PMID: 33229176.
• Yu SN, Nakanishi K, Ginns JN, Salna MP, Shimada YJ, Polanco A, Chiang Y, Weiner SD, Takayama H. Importance of surgical expertise in septal myectomy for obstructive hypertrophic cardiomyopathy. Gen Thorac Cardiovasc Surg. 2020;68(10):1094-1100. PMID: 32103394.
• Kuno T, Tanimoto E, Morita S, Shimada YJ. Effects of Bariatric Surgery on Cardiovascular Disease: A Concise Update of Recent Advances. Front Cardiovasc Med. 2019;6:94. Review. PMID: 31355210.
• Shimada YJ. Is leptin protective against heart failure with preserved ejection fraction? A complex interrelationship among leptin, obesity, and left ventricular hypertrophy. Hypertens Res. 2019 Feb;42(2):141-142. Editorial. PMID: 30420723.
• Chiang YP, Shimada YJ, Ginns J, Weiner SD, Takayama H. Septal myectomy for hypertrophic cardiomyopathy: important surgical knowledge and technical tips in the era of increasing alcohol septal ablation. Gen Thorac Cardiovasc Surg. 2018;66(4):192-200. Review. PMID: 29450766.
• Shimada YJ, Weiner S, Takayama H. How AMAZING is A MAZE Procedure in the HOCM Population? Journal of Thoracic and Cardiovascular Surgery. 2017;155(4):1543-1544 . Editorial. PMID: 28974318.
• Mohajer P, Shimada YJ. Reducing the risk of heart failure exacerbation by bariatric surgery in obese patients. Expert Review of Endocrinology & Metabolism. 2016;11(5):369-371. PMID: 30058904.
• Shimada YJ, Cannon CP. PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future. Eur Heart J. 2015;36(36):2415-24. Review. PMID: 25971287.
• Shimada YJ and Scirica BM. Long Term Management and Unmet Needs after an Acute Coronary Syndrome Event. Am J Cardiol. Review. 2015;115(5 Suppl):29A-35A. PMID: 25728972.
• Shimada YJ, Giugliano RP. Emerging Antithrombotic Drugs for Acute Coronary Syndrome. Expert Opin Emerg Drugs. 2013;18(3):307-18. Review. PMID: 23848430.

• Shimada YJ, Fifer MA, "Assessment of Heart Failure: Invasive and Noninvasive Methods [chapter in textbook]," in Hypertrophic Cardiomyopathy, Third Edition. ed. Naidu SS. (Springer, anticipated publication in 2023).
• Shimada YJ, Baggish AL, and Fifer MA, "Assessment of Heart Failure: Invasive and Noninvasive Methods [chapter in textbook]," in Hypertrophic Cardiomyopathy, Second Edition, pp. 93-106. ed. Naidu SS. (Springer, 2018).

• Akita K, Shimada YJ[last author], et al. Prediction of Cardiac Death in Patients with Hypertrophic Cardiomyopathy Using RNA-Sequencing of Plasma Small Non-coding RNAs [abstract]. Eur Heart J. 2023 (accepted).
• Akita K, Shimada YJ[last author], et al. Prediction of Acute Heart Failure Events in Patients with Hypertrophic Cardiomyopathy Using RNA-Sequencing of Plasma Small Non-coding RNAs [abstract]. Eur Heart J. 2023 (accepted).
• Akita K, Shimada YJ[last author], et al. Deep learning analysis of echocardiographic images to predict late gadolinium enhancement on cardiac magnetic resonance in patients with hypertrophic cardiomyopathy. JACC 2023.
• Sewanan LR, Shimada YJ[last author], et al. Comprehensive proteomic profiling reveals differentially regulated signaling pathways underlying left ventricular hypertrophy between hypertrophic cardiomyopathy and aortic stenosis. JACC 2023.
• Akita K, Shimada YJ[last author], et al. Association of plasma adiponectin and leptin levels with all-cause mortality and new-onset ventricular tachyarrhythmias in patients with hypertrophic cardiomyopathy. Circulation 2022.
• Lumish H, Shimada YJ[last author], et al. Comprehensive proteomics profiling of myocardium identifies dysregulated signaling pathways in hypertrophic cardiomyopathy. Circulation 2022.
• Osawa I, Shimada YJ[last author], et al. Comparative effectiveness of alcohol septal ablation versus septal myectomy on mortality in patients with hypertrophic cardiomyopathy. Circulation 2022.
• Osawa I, Shimada YJ, et al. Identifying target populations for extracorporeal cardiopulmonary resuscitation among patients with refractory out-of-hospital cardiac arrest using machine learning. Circulation 2022.
• Young Investigator Award Competition Finalist: Lumish H, Shimada YJ[last author], et al. Prediction of worsening heart failure in patients with hypertrophic cardiomyopathy using plasma proteomics profiling[abstract]. Eur Heart J. 2022.
• Lee C, Shimada YJ[last author], et al. Proteomics profiling reveals signaling pathways associated with major adverse cardiovascular events in patients with hypertrophic cardiomyopathy[abstract]. Eur Heart J. 2022.
• Harano N, Shimada YJ[last author], et al. Prediction of new-onset atrial fibrillation in patients with hypertrophic cardiomyopathy using proteomics profiling[abstract]. Eur Heart J. 2022.
• Shimada YJ, et al. Comprehensive sequencing of small non-coding RNA reveals plasma circulating biomarkers of hypertrophic cardiomyopathy and dysregulated signaling pathways[abstract]. Circulation 2021;144:A1331.
• Shimada YJ, et al. Comprehensive proteomics profiling reveals molecular pathways that are differentially regulated in hypertrophic cardiomyopathy and correlate with clinical markers of disease severity[abstract]. Eur Heart J. 2021.
• Shimada YJ, et al. Prediction of major adverse cardiovascular events in patients with hypertrophic cardiomyopathy using proteomics profiling[abstract]. Eur Heart J. 2021.
• Miyashita S, Shimada YJ[last author], et al. Bariatric surgery is associated with lower risk of acute cardiovascular event in patients with obesity and hypertrophic cardiomyopathy[abstract]. Eur Heart J. 2021.
• Lander BS, Shimada YJ[last author], et al. Comprehensive proteomics profiling identifies patients with late gadolinium enhancement on cardiac magnetic resonance imaging in the hypertrophic cardiomyopathy population[abstract]. Eur Heart J. August 2021.
• Liang LW, Shimada YJ[last author], et al. Proteomics profiling reveals distinct molecular subtypes of hypertrophic cardiomyopathy with different risks of major adverse cardiovascular events[abstract]. Eur Heart J. August 2021.
• Liang LW, Shimada YJ[last author], et al. Prediction of genotype positivity in patients with hypertrophic cardiomyopathy using machine learning [abstract]. J Am Coll Cardiol. 2021.
• Morita SX, Shimada YJ[last author], et al. Effects of septal reduction therapy on acute cardiovascular events and all-cause mortality in patients with obstructive hypertrophic cardiomyopathy: propensity score-matched study[abstract]. Circulation. 2020;142:A14301.
• Morita SX, Shimada YJ[last author], et al. Deep convolutional neural network analysis of echocardiographic images improves prediction of genotype positivity in patients with hypertrophic cardiomyopathy[abstract]. Circulation. 2020;142:A14299.
• Kochav SM, Shimada YJ[last author], et al. Machine learning-based prediction of cardiovascular death in patients with hypertrophic cardiomyopathy [abstract]. Circulation. 2019;140:A12324.
• Shimada YJ, et al. Proteomics profiling reveals molecular pathways enriched in hypertrophic cardiomyopathy [abstract]. Circulation. 2018;138:A11588.
• Shimada YJ, et al. Comparative effectiveness of alcohol septal ablation versus septal myectomy on acute care use for cardiovascular disease in patients with hypertrophic cardiomyopathy. European Heart Journal. 2018;39 (suppl_1):3547.
• Shimada YJ, et al. Comparative effectiveness of gastric bypass versus gastric banding on the risk of acute care use for cardiovascular disease in obese adults. Circulation. 2017;136:A17189.
• Shimada YJ, et al. Bariatric Surgery is Associated with Reduced Risk and Cost of Emergency Department Visits and Hospitalizations for Cardiovascular Disease. J Am Coll Cardiol. 2017;69 (11 Suppl.):1791.
• Shimada YJ, Farrell LA, Gerszten RE, Fifer MA. Diagnostic Value of Metabolite Profiling in Patients with Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2017;69 (11 Suppl.):837.
• Shimada YJ, et al. Bariatric Surgery is Associated with Reduced Risk of Hypertension-Related Emergency Department Visits and Unplanned Hospitalizations. Circulation. 2016;134:A14460.
• Shimada YJ, et al. Bariatric Surgery is Associated with Reduced Risk of Hospitalizations for Stable Angina Pectoris in Obese Adults. Circulation. 2016;134:A14486.
• Shimada YJ, et al. Bariatric Surgery is Associated with Reduced Rate of Emergency Department Visits and Hospitalizations for Heart Failure Exacerbation among Obese Patients with Heart Failure. Circulation. 2015;132:A12343.
• Shimada YJ, et al. Association Between Bariatric Surgery and Emergency Department Visits and Hospitalizations for Atrial Fibrillation. Circulation. 2015;132:A13185.
• Shimada YJ, et al. Cardiac Ischemic Outcomes and Hospitalizations in Patients with Type 2 Diabetes and Recent Acute Coronary Syndrome treated with Alogliptin or placebo: New Insights from the EXAMINE trial. Ned Tijdschr Diabetol 2015;13:76–77.
• McCullough SA, Shimada YJ, Baggish AL, Lowry PA, O’Callaghan C, Rothman RD, Vlahakes GJ, and Fifer MA. Right Heart Failure Predicts Higher Mortality in Patients With Hypertrophic Cardiomyopathy. Circulation. 2014;130:A12390.
• Shimada YJ, Passeri JJ, Baggish AL, O'Callaghan C, Lowry PA, Yannekis G, Abbara S, Ghoshhajra BB, Rothman RD, Ho CY, Januzzi JL, Seidman CE, Fifer MA. Attenuation of Left Ventricular Fibrosis by Losartan in Patients with Nonobstructive Hypertrophic Cardiomyopathy: A Randomized, Placebo Controlled, Double Blind Study. Circulation. 2013; 128: A10336.
• Shimada YJ, Shiota T. Underestimation of Left Ventricular Mass by 3-Dimensional Echocardiography Validated by Magnetic Resonance Imaging: A Meta-Analysis and Investigation of the Source of Bias. J Am Coll Cardiol. 2011;57:E753.
• Shimada YJ, Schweitzer P. Prognostic Impact of Terminal T Wave Inversion on Presentation in Patients with ST-Elevation Myocardial Infarction Treated with Urgent Percutaneous Coronary Intervention. J Am Coll Cardiol. 2011;57:E1810.
• Shimada YJ and Kato S (first co-author), Bergmann RS, et al. Inadequacy of Current Deep Venous Thrombosis Prophylaxis in Medical Inpatients with a Prior History of Venous Thromboembolism. Circulation. 2010;122(21(suppl.)):A13287.
• Shimada YJ, Shiota T. Underestimation of Left Atrial Volume by 3-Dimensional Echocardiography Validated by Magnetic Resonance Imaging: A Meta-Analysis and Investigation of the Source of Bias. Circulation. 2010;122(21(suppl.)):A18481.
• Shimada YJ, Shiota T. Accuracy of Right Ventricular Volumes and Function Determined by 3-Dimensional Echocardiography in Comparison with Magnetic Resonance Imaging: A Meta-analysis Study. J Am Coll Cardiol 2010;55(10) (suppl.A);A76.
• Shimada YJ, Shiota T. Accuracy of Left Ventricular Volumes and Function Determined by 3-Dimensional Echocardiography Validated by Magnetic Resonance Imaging: A Meta-analysis and Investigation for the source of bias. J Am Coll Cardiol 2010;55(10)(suppl.A);A77.
• Shimada YJ, Kanei Y, Schweitzer P. Additional Value of Initial Electrocardiogram for Early Risk-Stratification in Patients with ST-elevation Myocardial Infarction. Chest. 2009;136(4)(suppl):e556.
• Shimada YJ, Kanei Y. Less Heparin is Necessary for Asian Patients Undergoing Percutaneous Coronary Intervention. Catheterization and Cardiovascular Interventions. 2009;73(7)(suppl):C29.
• Shimada YJ, Kanei Y. Less Heparin per Weight is Necessary for Obese Patients Undergoing Percutaneous Coronary Intervention.  J Am Coll Cardiol 2009;53(10) (suppl.A);A67.

Dr. Shimada has served as the sole Principal Investigator on the following research grants:

• NIH/NHLBI, R01 grant (R01-HL168382)
• NIH/NHLBI, R01 grant (R01-HL157216)
• American Heart Association, Career Development Award (18CDA34110245)
• American Heart Association, National Clinical and Population Research Award (17MCPRP33670415)
• American Heart Association, National Clinical and Population Research Award (15CRP22930001)
• Feldstein Medical Foundation
• Korea Institute of Oriental Medicine (W22005)
• Korea Institute of Oriental Medicine (K18190)
• Columbia University Irving Medical Center, Marjorie and Lewis Katz Cardiovascular Research Prize
• Columbia University Irving Medical Center, Precision Medicine Pilot Award
• Bristol Myers Squibb